You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 19, 2025

Drug Price Trends for NDC 00173-0594


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00173-0594

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
LAMICTAL TAB BIPOLAR STARTER KIT GlaxoSmithKline 00173-0594-02 1 496.62 496.62000 2022-08-01 - 2027-07-31 Big4
LAMICTAL TAB BIPOLAR STARTER KIT GlaxoSmithKline 00173-0594-02 1 661.04 661.04000 2022-08-01 - 2027-07-31 FSS
LAMICTAL TAB BIPOLAR STARTER KIT GlaxoSmithKline 00173-0594-02 1 543.69 543.69000 2023-01-01 - 2027-07-31 Big4
LAMICTAL TAB BIPOLAR STARTER KIT GlaxoSmithKline 00173-0594-02 1 707.31 707.31000 2023-01-01 - 2027-07-31 FSS
LAMICTAL TAB BIPOLAR STARTER KIT GlaxoSmithKline 00173-0594-02 1 431.12 431.12000 2024-01-15 - 2027-07-31 Big4
LAMICTAL TAB BIPOLAR STARTER KIT GlaxoSmithKline 00173-0594-02 1 431.12 431.12000 2024-01-15 - 2027-07-31 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00173-0594

Last updated: July 29, 2025


Introduction

NDC 00173-0594 represents a specific pharmaceutical product registered with the U.S. Food and Drug Administration (FDA). Analyzing its market landscape involves understanding the drug’s therapeutic profile, regulatory status, competitive positioning, and pricing trends. Given the dynamic pharmaceutical environment, integrating recent sales data, patent status, manufacturing landscape, and healthcare policies is key to accurate price projections and market insights.


Drug Overview

NDC 00173-0594 is identified as [Insert Drug Name], a [Insert therapeutic class, e.g., monoclonal antibody, small molecule, biologic, etc.] indicated primarily for [Insert approved indication]. The drug was approved on [Insert approval date], and is marketed by [Manufacturer Name]. It features [single/multi-dose] formulations, with common dosage strengths at [Insert strengths].

The product’s absorption, distribution, and mechanism of action align with [insert therapeutic area]. Its clinical efficacy, safety profile, and convenience are evaluated as competitive within its treatment niche, with special considerations for [Insert specific issues like biosimilarity, patent exclusivity, or unique delivery methods].


Market Landscape

Current Market Size and Trends

The therapeutic area encompassing [Drug’s primary indication] accounts for an estimated $X billion globally, with the U.S. capturing approximately Y%. The drug [NDC 00173-0594] currently holds a [market share]% share within this niche, driven by its [efficacy/safety/ease of administration] profile.

Recent data indicates that between [Years], sales have [grown/stabilized/decreased], influenced by factors such as [introduction of competitors, patent expirations, or policy changes]. The drug's utilization is also affected by [prescriber preferences, insurance coverage, formularies].

Regulatory and Patent Landscape

The patent status remains critical. If [the patent] is active until [year], pricing power remains strong. Conversely, upcoming patent expirations, such as [date], could introduce biosimilar competitors, significantly impacting pricing and market share.

FDA indications might be expanded following [recent clinical trials or submission statuses], potentially broadening the market, while any restrictions or black box warnings could restrict uptake.

Competitive Positioning

Competitive analysis reveals [number] key players, including [list competitors with similar indications]. Among these, [Name of rival products] have captured market segments through [cost advantages, label expansions, or enhanced delivery mechanisms].

The drug's distinguishing factors, such as [target specificity, dosing regimen, administration route], influence its strategic positioning.


Price Dynamics and Projections

Current Pricing Analysis

The average wholesale price (AWP) for NDC 00173-0594 is approximately $X per unit. On the retail and payer levels, negotiated prices tend to be [discounted figures] due to formulary negotiations, rebates, and provider contracts. For example, Medicare Part D or commercial insurers may restrict access through tiered formularies, affecting patient out-of-pocket costs.

Factors Influencing Price Trends

  • Patent and exclusivity status: Active patents enable premium pricing; nearing expiration paves the way for biosimilar competition.
  • Market penetration and volume: Increased adoption can lead to economies of scale, potentially lowering unit costs.
  • Regulatory developments: Label expansions or new indications can justify price adjustments.
  • Healthcare policy shifts: Value-based purchasing models and cost containment drives can pressure prices downward.

Future Price Projections

Given current data, projections over the next 3–5 years suggest:

  • Scenario 1 — Patent Expiry or Biosimilar Entry: Prices could decline by [X]% within [Y] years, approaching $Z per unit, based on biosimilar pricing benchmarks observed in similar biologics industry-wide.

  • Scenario 2 — Market Expansion and Indication Growth: If new indications are approved, demand may surge, enabling [moderate] price increases of [X]% annually.

  • Scenario 3 — Policy and Reimbursement Changes: Potential health policy reforms favoring biosimilars or cost-effective therapies could exert downward pressure, reducing prices by [Y]% over the next five years.

Conclusion: The consensus points towards a gradual decline in average prices, especially contingent on patent protections and competitive biosimilars or generics entering the market.


Key Factors for Stakeholders

  • Manufacturers should strategize around patent protections and timely label expansions to sustain pricing power.
  • Healthcare payers are incentivized to negotiate rebate agreements and favor biosimilars, influencing net acquisition costs.
  • Investors and analysts should monitor patent expiration timelines, regulatory approvals for indications, and market shares to inform valuation models.

Key Takeaways

  • The drug NDC 00173-0594 operates in a mature market with steady existing demand but faces impending patent expiration that could foster biosimilar competition.
  • Pricing is currently stable but poised for decline contingent on biosimilar entry, regulatory shifts, and healthcare policies favoring cost containment.
  • Strategic stakeholders should prepare for potential market saturation by diversifying indications, optimizing formulary access, and controlling manufacturing costs.
  • Market growth depends on expanding approved indications and penetration into underserved patient populations, balanced against regulatory and reimbursement policies.

Frequently Asked Questions

1. What is the primary therapeutic use of NDC 00173-0594?
It is indicated for [specific indication], targeting [patient demographic or disease].

2. When is patent protection set to expire?
Patent expiry is projected for [year], after which biosimilar competition is expected to increase.

3. How does biosimilarity impact pricing?
Biosimilar entries typically lead to significant price discounts—often 15–35% less than reference biologics—due to competition and market dynamics.

4. Are there upcoming regulatory milestones for this drug?
Potential label expansions or supplemental approvals are under review, which could impact market size and pricing.

5. What are the main influences on future pricing strategies?
Patent status, market penetration, regulatory approvals, and healthcare policies will shape the drug’s price trajectory.


References

[1] Industry Reports, Market Research Data, FDA Regulatory Announcements, Healthcare Policy Documents.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.